<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zabmedvestnik</journal-id><journal-title-group><journal-title xml:lang="ru">Забайкальский медицинский вестник</journal-title><trans-title-group xml:lang="en"><trans-title>Transbaikalian Medical Bulletin</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">1998-6173</issn><publisher><publisher-name>Читинская государственная медицинская академия</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52485/19986173_2025_3_51</article-id><article-id custom-type="elpub" pub-id-type="custom">zabmedvestnik-436</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ ПОЛА, ВОЗРАСТА И МЕДИЦИНСКОЙ ДЕЯТЕЛЬНОСТИ НА ЭФФЕКТИВНОСТЬ ЭРАДИКАЦИИ HELICOBACTER PYLORI</article-title><trans-title-group xml:lang="en"><trans-title>THE ROLE OF GENDER, AGE AND MEDICAL ACTIVITIES IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8282-3056</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лузина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Luzina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лузина Елена Владимировна, к.м.н., доцент, доцент кафедры терапии факультета дополнительного профессионального образования, председатель Забайкальского научного общества гастроэнтерологов</p><p>672000, г. Чита, ул. Горького, 39а</p></bio><bio xml:lang="en"><p>Luzina E.V., Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Therapy Faculty of Additional Professional Education; Chairman of the Trans-Baikal Scientific Society of Gastroenterologists</p><p>39A Gorky St., Chita, Russia, 672000</p></bio><email xlink:type="simple">el.luz@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8736-5851</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазебник</surname><given-names>Л. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazebnik</surname><given-names>L. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лазебник Леонид Борисович, д.м.н., профессор, профессор кафедры терапии и профилактической медицины; президент Научного общества гастроэнтерологов России; вице-президент Российского научного медицинского общества терапевтов</p><p>г. Москва, ул. Долгоруковская, д. 4</p><p>Scopus Author ID: 7005446863</p></bio><bio xml:lang="en"><p>Lazebnik L.B., Doctor of Medical Sciences, Professor, Professor of the Department of Internal Medicine and Preventive Medicine, President of the GSSR, Vice President of the RSMST</p><p>Dolgorukovskaya St., Moscow, 127006</p><p>Scopus Author ID: 7005446863</p></bio><email xlink:type="simple">leonid.borisl@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9498-9216</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lareva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ларёва Наталья Викторовна, д.м.н., профессор, исполняющая обязанности ректора, проректор по научной и международной работе, заведующая кафедрой терапии факультета дополнительного профессионального образования; председатель Забайкальского регионального отделения РНМОТ</p><p>672000, г. Чита, ул. Горького, 39а</p></bio><bio xml:lang="en"><p>Lareva N.V., Doctor of Medical Sciences, Professor, Acting Rector, Vice-rector for Research and International Affairs, Head of the Department of Therapy Faculty of Additional Professional Education; Chairman of the Trans-Baikal Regional Branch of the Russian Scientific Medical Society of Internal Medicine</p><p>39A Gorky St., Chita, Russia, 672000</p></bio><email xlink:type="simple">larevanv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-5773-0720</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Филиппова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Filippova</surname><given-names>Anna A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Филиппова Анна Анатольевна, к.м.н., ассистент кафедры терапии факультета дополнительного профессионального образования</p><p>672000, г. Чита, ул. Горького, 39а</p></bio><bio xml:lang="en"><p>Filippova A.A., Candidate of Medical Sciences, Assistant of the Department of Therapy of the Faculty of Additional Professional Education</p><p>39A Gorky St., Chita, Russia, 672000</p></bio><email xlink:type="simple">zuevaaa@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-0990-4351</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богатикова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogatikova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богатикова Евгения Викторовна, врач-гастроэнтеролог</p><p>672007, г. Чита, ул. Генерала Белика, 10а, пом. 2</p></bio><bio xml:lang="en"><p>Bogatikova E.V., gastroenterologist</p><p>10А/2 General Belik St., Chita, 972007</p></bio><email xlink:type="simple">bogatikova_evgenia@list.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Читинская государственная медицинская академия» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chita State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский университет медицины» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Медицинский центр «Эталон мед»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>ETALON MED Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>11</month><year>2025</year></pub-date><volume>0</volume><issue>3</issue><fpage>51</fpage><lpage>62</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лузина Е.В., Лазебник Л.Б., Ларева Н.В., Филиппова А.А., Богатикова Е.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Лузина Е.В., Лазебник Л.Б., Ларева Н.В., Филиппова А.А., Богатикова Е.В.</copyright-holder><copyright-holder xml:lang="en">Luzina E.V., Lazebnik L.B., Lareva N.V., Filippova A.A., Bogatikova E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.zabmedvestnik.ru/jour/article/view/436">https://www.zabmedvestnik.ru/jour/article/view/436</self-uri><abstract><p>Цель исследования – анализ результатов лечения Helicobacter pylori (H. pylori) схемой первой линии с висмутом у жителей Забайкальского края в зависимости от пола, возраста и медицинской деятельности.Материалы и методы. Проведена эрадикация H. pylori схемой первой линии (ингибитор протоновой помпы, кларитромицин, амоксициллин) и висмута трикалия дицитрат в рекомендованных дозах в течение 14 дней у 116 человек. Из них 82 женщины и 34 мужчин, 59 лиц в возрасте 20–50 лет и 57 человек – 51–65 лет, 52 субъекта – медицинские и 64 – немедицинские работники. Контроль эрадикации проведен через 6–8 недель после окончания лечения при исследовании антигена H. pylori в кале иммунохроматографическим анализом. Во время курса эрадикации анализировались нежелательные явления (НЯ).Статистические методы: описательная статистика, χ2 Пирсона, отношение шансов (биостатистика).Результаты. Эффективность эрадикации H. pylori в исследуемой группе составила 71,5%, у медицинских работников – 57,7%, у немедицинского персонала – 82,8% (р = 0,003). Более успешное лечение зарегистрировано у женщин в группе немедицинских работников (92,1%) в отличие от мужчин этой группы (69,2%, р = 0,018) и женщин-медиков (52,3%, р &lt; 0,001). Немедицинские работники 20–50 лет демонстрировали лучшие результаты эрадикации – 93,3%, пациенты 51–65 лет этой же группы – 73,5% (р = 0,037), медики 20–50 лет – 58,6% (р = 0,002). В медицинской среде половых и возрастных различий получено не было. НЯ зарегистрированы у 64 человек (55,2%): у 35 (67,3%) медицинских и у 29 (45,3%) немедицинских работников. Мужчины-медики отмечали НЯ в 2,5 раза чаще, чем мужчины других отраслей (р = 0,009).Заключение. Вероятность успешной эрадикации H. pylori выше у женщин младше 50 лет, не имеющих отношения к медицинской деятельности. У медицинских работников уничтожение H. pylori происходит существенно реже без половых и возрастных различий при более высокой частоте НЯ, особенно у мужчин.</p></abstract><trans-abstract xml:lang="en"><p>The aim of the research. Analysis of the results of Helicobacter pylori (H. pylori) treatment with the firstline regimen and bismuth in residents of the Transbaikal region depending on gender, age and medical activity.Materials and methods. H. pylori eradication was performed using a first-line regimen (proton pump inhibitor, clarithromycin, amoxicillin) and bismuth tripotassium dicitrate at recommended doses for 14 days in 116 people. Of these, 82 were women and 34 were men, 59 were aged 20–50 years and 57 were aged 51– 65 years, 52 were medical staff and 64 were non-medical. Eradication control was performed 6–8 weeks after treatment with H. pylori antigen in feces using immunochromatographic analysis. During treatment, adverse events (AE) were analyzed.Statistical methods: descriptive statistics, x2-test, odds ratio (OR) (biostatistics). Results. The efficiency of H. pylori eradication in the study group was 71,5%, among medical staff – 57,7%, among non-medical – 82,8% (p = 0,003). More successful treatment was observed among female non-medical (92,1%), in contrast to male non-medical (69,2%, p = 0,018) and female medical staff (52,3%, p &lt; 0,001).Non-medical aged 20–50 demonstrated the best eradication results – 93,3%, patients aged 51–65 nonmedical – 73,5% (p = 0,037), medical staff aged 20–50 – 58,6% (p = 0,002). There were no gender or age differences in the group of medical staff. AE were registered in 64 people (55,2%): 35 (67,3%) medical staff and 29 (45,3%) non-medical. AE were 2,5 times more common in male medical staff than in men in other specialties (p = 0,009).Conclusion. Probability of H. pylori eradication is higher in women under 50 years of age who are not medically active. H. pylori eradication is less common in medical staff with-out gender or age differences, with a higher incidence of AE, especially in men.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>внутренние болезни</kwd><kwd>Helicobacter pylori</kwd><kwd>лечение</kwd><kwd>пол</kwd><kwd>возраст</kwd><kwd>медицинские работники</kwd></kwd-group><kwd-group xml:lang="en"><kwd>internal medicine</kwd><kwd>Helicobacter pylori</kwd><kwd>treatment</kwd><kwd>gender</kwd><kwd>age</kwd><kwd>medical staff</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Malfertheiner P., Megraud F., Rokkas Th., et al. Management of Helicobacter pylori infection: the MaastrichtVI/Florence consensus report. Gut. 2022. gutjnl-2022-327745. DOI 10.1136/gutjnl-2022-327745.</mixed-citation><mixed-citation xml:lang="en">Malfertheiner P., Megraud F., Rokkas Th., et al. Management of Helicobacter pylori infection: the MaastrichtVI/Florence consensus report. Gut. 2022. gutjnl-2022-327745. DOI 10.1136/gutjnl-2022-327745.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник Л.Б., Дехнич Н.Н., Ситкин С.И. и соавт. Helicobacter pylori, хеликобактериоз и ассоциированные заболевания (VIII Московские соглашения по диагностике и лечению хеликобактериоза у взрослых и детей). Руководство для врачей. Экспериментальная и клиническая гастроэнтерология. 2024. (12). 49–145. DOI 10.31146/1682-8658-ecg-232-12-49-145.</mixed-citation><mixed-citation xml:lang="en">Lazebnik L.B., Dekhnich N.N., Sitkin S.I., et al. Helicobacter pylori, helicobacteriosis and associated diseases (VIII Moscow Agreements on the diagnosis and treatment of helicobacteriosis in adults and children) A Clinical Guide for Physicians. Eksperimental'naya i klinicheskaya gastroenterologiya. 2024. (12). 49–145. DOI 10.31146/1682-8658-ecg-232-12-49-145. in Russian.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Megraud F., Bruyndonckx R., Coenen S., et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021. 70 (10). 1815–1822. DOI 10.1136/gutjnl-2021-324032.</mixed-citation><mixed-citation xml:lang="en">Megraud F., Bruyndonckx R., Coenen S., et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021. 70 (10). 1815–1822. DOI 10.1136/gutjnl-2021-324032.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Маев И.В., Андреев Д.Н., Бордин Д.С., и соавт. Резистентность Helicobacter pylori к кларитромицину в Российской Федерации. Эффективная фармакотерапия. 2020. 16 (30). 16–22. DOI 10.33978/2307-3586-2020-16-30-16-22.</mixed-citation><mixed-citation xml:lang="en">Mayev I.V., Andreyev D.N., Bordin D.S. Helicobacter pylori Resistance to Clarithromycin in the Russian Federation. Effektivnaya farmakoterapiya. 2020. 16 (30).16–22. in Russian. DOI 10.33978/2307-3586-2020-16-30-16-22.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Бордин Д.С., Плавник Р.Г., Невмержицкий В.И., и соавт. Распространенность Helicobacter pylori среди медицинских работников Москвы и Казани по данным ¹³С-уреазного дыхательного теста. Альманах клинической медицины. 2018. 46 (1). 40–49. DOI 10.18786/2072-0505-2018-46-1-40-49. DOI 10.18786/2072-0505-2018-46-1-40-49.</mixed-citation><mixed-citation xml:lang="en">Bordin D.S., Plavnik R.G., Nevmerzhitskiy V.I., et al. Prevalence of Helicobacter pylori among medical workers in Moscow and Kazan according to ¹³С-urease breath test. Al'manakh klinicheskoy meditsiny. 2018. 46 (1). 40–49. DOI 10.18786/2072-0505-2018-46-1-40-49. in Russian.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mori H., Suzuki H., Omata F. et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019. 12. 1756284819858511. DOI 10.1177/1756284819858511.</mixed-citation><mixed-citation xml:lang="en">Mori H., Suzuki H., Omata F. et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019. 12. 1756284819858511. DOI 10.1177/1756284819858511.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кукес В.Г., Грачев С.В., Сычев Д.А., Раменская Г.В. Метаболизм лекарственных средств. Научные основы персонализированной медицины: руководство для врачей. М. ГЭОТАР-Медиа. 2008. 304 с.</mixed-citation><mixed-citation xml:lang="en">Kukes V.G., Grachev S.V., Sychev D.A., Ramenskaya G.V. Metabolism of drugs. The Scientific Foundations of Personalized Medicine: A Guide for Physicians. M. GEOTAR-Media. 2008. 304 p. in Russian.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Лапина Т.Л., Маев И.В., и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022. 32 (6). 72–93. DOI 10.22416/1382-4376-2022-32-6-72-93.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Lapina T.L., Maev I.V., et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for Н. pylori Diagnostics and Treatment in Adults. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2022. 32 (6). 72–93. in Russian. DOI 10.22416/1382-4376-2022-32-6-72-93.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nyssen O.P., Bordin D., Tepes B., et al. European Registry on management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021. 70 (1). 40–54. DOI 10.1136/gutjnl-2020-321372.</mixed-citation><mixed-citation xml:lang="en">Nyssen O.P., Bordin D., Tepes B., et al. European Registry on management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021. 70(1). 40-54. DOI 10.1136/gutjnl-2020-321372.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jonaitis P., Nyssen O.P., Saracino I.M., et al. Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023. 13 (1). 17235. DOI 10.1038/s41598-023-43287-4.</mixed-citation><mixed-citation xml:lang="en">Jonaitis P., Nyssen O.P., Saracino I.M., et al. Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023. 1 (1). 17235. DOI 10.1038/s41598-023-43287-4. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kusunoki M., Yuki M., Ishitobi H., et al. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori. Intern Med. 2019. 58 (11). 1549–1555. DOI 10.2169/internalmedicine.2233-18.</mixed-citation><mixed-citation xml:lang="en">Kusunoki M., Yuki M., Ishitobi H., et al. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori. Intern Med. 2019. 58 (11). 1549–1555. DOI 10.2169/internalmedicine.2233-18.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tang Y., Tang G., Pan L., et al. Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China. Sci. Rep. 2020. 10. 15403. DOI 10.1038/s41598-020-72400-0.</mixed-citation><mixed-citation xml:lang="en">Tang Y., Tang G., Pan L., et al. Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China. Sci. Rep. 2020. 10. 15403. DOI 10.1038/s41598-020-72400-0.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yokota N., Ae R., Amenomori M., et al. Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care. J Gen Fam Med. 2019. 20 (4). 139–145. DOI 10.1002/jgf2.245.</mixed-citation><mixed-citation xml:lang="en">Yokota N., Ae R., Amenomori M., et al. Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care. J Gen Fam Med. 2019. 20 (4). 139-145. DOI 10.1002/jgf2.245.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ma T-L., Tai W-Ch., Loke S-S., et al. Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly. Drugs Aging. 2023. 40 (1). 71–79. DOI 10.1007/s40266-022-00990-7.</mixed-citation><mixed-citation xml:lang="en">Ma T-L., Tai W-Ch., Loke S-S., et al. Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly. Drugs Aging. 2023. 40 (1). 71–79. DOI 10.1007/s40266-022-00990-7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Huang T-T., Cao Y-X., Cao L. Novel therapeutic regimens against Helicobacter pylori: an updated systematic review. Front Microbiol. 2024. 15. 1418129. DOI 10.3389/fmicb.2024.1418129.</mixed-citation><mixed-citation xml:lang="en">Huang T-T., Cao Y-X., Cao L. Novel therapeutic regimens against Helicobacter pylori: an updated systematic review. Front Microbiol. 2024. 15. 1418129. DOI 10.3389/fmicb.2024.1418129.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">González-Hormazábal P., Arenas A., Serrano C. et al. Prevalence of Helicobacter pylori Antimicrobial Resistance Among Chilean Patients. Arch Med Res. 2021. 52 (5). 529–534. DOI 10.1016/j.arcmed.2021.01.011.</mixed-citation><mixed-citation xml:lang="en">González-Hormazábal P., Arenas A., Serrano C., et al. Prevalence of Helicobacter pylori Antimicrobial Resistance Among Chilean Patients. Arch Med Res. 2021. 52 (5). 529–534. DOI 10.1016/j.arcmed.2021.01.011.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Маев И.В., Мкртумян А.М., Бектемирова Л.Г., Андреев Д.Н., Дичева Д.Т. Эффективность эрадикационной терапии 1-й линии при инфекции Helicobacter pylori у пациентов с сахарным диабетом 2-го типа. Терапевтический архив. 2022. 94 (2). 209–215. DOI 10.26442/00403660.2022.02. 201372.</mixed-citation><mixed-citation xml:lang="en">Mayev I.V., Mkrtumyan A.M., Bektemirova L.G., Andreyev D.N., Dicheva D.T. The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus. Terapevticheskii Arkhiv. 2022. 94 (2). 209–215. In Russian. DOI 10.26442/00403660.2022.2.201372.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Qiao Y., Zhou Y., Zhao L., et al. Sex differences in Helicobacter pylori infection and recurrence rate among 81,754 Chinese adults: a cross-sectional study. BMC Gastroenterol. 2024. 24 (1). 305. DOI 10.1186/s12876-024-03404-7.</mixed-citation><mixed-citation xml:lang="en">Qiao Y., Zhou Y., Zhao L., et al. Sex differences in Helicobacter pylori infection and recurrence rate among 81,754 Chinese adults: a cross-sectional study. BMC Gastroenterol. 2024. 24 (1). 305. DOI 10.1186/s12876-024-03404-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Morilla A.M., Álvarez-Argüelles M.E., Duque J.M., et al. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol Hepatol. 2019. S0210-5705(19)30129-3. DOI 10.1016/j.gastrohep.2019.05.002.</mixed-citation><mixed-citation xml:lang="en">Morilla A.M., Álvarez-Argüelles M.E., Duque J.M., et al. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol Hepatol. 2019. S0210-5705(19)30129-3. DOI 10.1016/j.gastrohep.2019.05.002. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Якушева Е.Н., Щулькин А.В., Попова Н.М., Черных И.В., Титов Д.С. Структура, функции гликопротеина-Р и его значение для рациональной фармакотерапии. Обзоры по клинической фармакологии и лекарственной терапии. 2014. 12 (2). 3–11.</mixed-citation><mixed-citation xml:lang="en">Yakusheva E.N., Shchul'kin A.V., Popova N.M., Chernykh I.V., Titov D.S. Structure, functions of P-glycoprotein and its role in rational pharmacotherapy. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii. 2014. 12 (2). 3–11. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Бакулина Н.В., Симаненков В.И., Бакулин И.Г., Ильчишина Т.А. Распространенность хеликобактерной инфекции среди врачей. Экспериментальная и клиническая гастроэнтерология. 2017. 148 (12). 20–24.</mixed-citation><mixed-citation xml:lang="en">Bakulina N.V., Simanenkov V.I., Bakulin I.G., Ilchishina T.A. Prevalence of helicobacter pylori infection among physicians. Eksperimental'naya i klinicheskaya gastroenterologiya. 2017. 148 (12). 20–24. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jonaitis P., Kupcinskas J., Gisbert J.P., Jonaitis L. Helicobacter pylori Eradication Treatment in Older Patients. Drugs Aging. 2024. 41 (2). 141–151. DOI 10.1007/s40266-023-01090-w.</mixed-citation><mixed-citation xml:lang="en">Jonaitis P., Kupcinskas J., Gisbert J.P., Jonaitis L. Helicobacter pylori Eradication Treatment in Older Patients. Drugs Aging. 2024. 41 (2). 141–151. DOI 10.1007/s40266-023-01090-w.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Велиев А.М., Маев И.В., Андреев Д.Н., и соавт. Эффективность и безопасность квадротерапии без препаратов висмута при лечении пациентов с Helicobacter pylori-ассоциированной язвенной болезнью желудка и двенадцатиперстной кишки. Терапевтический архив. 2019. 91 (8). 28–33. DOI 10.26442/00403660.2019.08.000382.</mixed-citation><mixed-citation xml:lang="en">Veliev A.M., Maev I.V., Andreev D.N. et al. The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease. Terapevticheskii arkhiv. 2019. 91 (8). 28–33. DOI 10.26442/00403660.2019.08.000382. in Russian.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
